TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02697474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Euvax B®: Hepatitis B vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Euvax B®: Hepatitis B vaccine
Description: 0.5 mL, Intramuscular
Study: NCT02538913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Daily pelvic floor muscle training and individualized regular exercise training (aerobic and strength exercise) three days per week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
Study: NCT01970098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, High dose
Description: 28 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, Low dose
Description: 28 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 28 weeks
Study: NCT03284541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2GETHER
Description: Communication skills, coping skills, problem-solving, acceptance, HIV prevention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Existing Public Health Practice
Description: HIV testing, medication adherence, HIV risk reduction
Study: NCT00892983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAB
Description: Standard well child care plus 7 extra parent contacts for augmented education and support around breast feeding, food and activity with 1 before birth and then at 1-2 weeks, and 3, 4, 7, 9, 13, and 18 months post-partum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAB
Description: Standard well child care plus 7 extra parent contacts for augmented education and support around breast feeding, food and activity with 1 before birth and then at 1-2 weeks, and 3, 4, 7, 9, 13, and 18 months post-partum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep
Description: Standard well child care plus 2 extra contacts focussed on Sleep with 1 before birth (anticipatory guidance), and sleep problem prevention at 3 weeks. A sleep problem intervention starting at 6 months was possible for those indicating their child had a sleep problem at 6 months of age. Main prevention advice focussed on placing baby to sleep awake, maximising night-day differences and use of sleep place in parents bedroom for first 6 months. Intervention after 6 months uses preferentially a technique called parental presence, and if this does not fit family a technique called camping out and finally, if neither of the first two fit family, controlled crying.
Study: NCT01484626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: The first group of three patients to enter the study will receive a 25 mg/m\^2 dose of bendamustine. If this dose is found to be safe, the next three patients will receive 50 mg/m\^2. Using a modified Fibonacci dose-escalation design, the dose will continue to increase at a rate of 25 mg/m\^2 until the highest safe dose of bendamustine is found. The maximum dose will be 125 mg/m\^2. Bendamustine and bortezomib will be given through a catheter twice a week every 21 days. Dexamethasone and lenalidomide will be given orally. In general, a cycle of chemotherapy will last 21 days.
Study: NCT00892983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep
Description: Standard well child care plus 2 extra contacts focussed on Sleep with 1 before birth (anticipatory guidance), and sleep problem prevention at 3 weeks. A sleep problem intervention starting at 6 months was possible for those indicating their child had a sleep problem at 6 months of age. Main prevention advice focussed on placing baby to sleep awake, maximising night-day differences and use of sleep place in parents bedroom for first 6 months. Intervention after 6 months uses preferentially a technique called parental presence, and if this does not fit family a technique called camping out and finally, if neither of the first two fit family, controlled crying.
Study: NCT02705066

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Cellulose
Study: NCT03353571

Intervention type: DEVICE
Group type: OTHER
Intervention: C3 UMBRELLA CATHETER
Description: The C3 is an alternative method to facilitate bladder drainage in the study population which are using either a foley catheter or Clean Intermittent Catheter technique to drain the bladder.
Study: NCT05262049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermittent compression-decompression with glides
Description: Patients in this group will be given only intermittent compression and decompression with glides. Traction (decompression applied at knee joint with anteroposterior glide followed by compression for about 6 minutes (30 glides, 10 seconds compression and vice versa), for the duration of 4 weeks (3 days a week, alternate days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: In this group conventional therapy will be given according to below mentioned protocol for 4 weeks (3 days a week, alternate days).~* Hot pack /TENS for 10 minutes~* Stretching: Hamstring(10x) and calf (10x)~* Strengthening of periarticular muscles especially the quadriceps (straight leg raising, pillow squeeze-isometric and dynamic)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy and intermittent compression-decompression with glides
Description: Patients in this group will receive the combination of conventional physical therapy and intermittent compression and decompression with glides, for 4 weeks (3 days a week, alternate days).
Study: NCT02814552

Intervention type: OTHER
Group type: OTHER
Intervention: HTN PRA App
Description: The HTN PRA App will be used to adjust standard of care medication dosages for high blood pressure drugs which may include: thiazide diuretic (water pill), usually called hydrochlorothiazide (HCTZ) or chlorthalidone, and an ACE inhibitor or an angiotensin receptor blocker.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample
Description: Blood sample for plasma renin activity activity will be obtained at least once (at baseline) and if BP is not controlled after 1-3 months, an additional blood sample may be obtained.
Study: NCT01668862

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Human Platelet Lysate
Description: Subjects will receive one injection of Autologous Human Platelet Lysate in the lateral epicondyle space

Intervention type: DRUG
Group type: OTHER
Intervention: Corticosteroid
Description: Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
Study: NCT02987868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid supplement first day
Description: An orally administered supplement of the proprietary amino acid derivative

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo first day
Description: A non-active orally administered supplement of the proprietary amino acid derivative
Study: NCT03553342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticoids
Description: Patients will receive corticosteroids therapy: 1mg/kg of prednisolone daily for seven days.
Study: NCT02987868

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amino acid supplement second day
Description: An orally administered supplement of the proprietary amino acid derivative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo second day
Description: A non-active orally administered supplement of the proprietary amino acid derivative
Study: NCT04456127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 Laser
Description: The UltraPulse® fractional ablative CO2 Laser will be employed with the DeepFX™ hand piece. Number of passes and laser settings, including fluency, density, spot size, will be chosen during the time of treatment as determined by the operating surgeon.
Study: NCT03438266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM VOLUMA® XC injectable gel with cannula
Description: Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.

Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM VOLUMA® XC injectable gel with needle
Description: Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
Study: NCT03553342

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo for seven days.
Study: NCT02350556

Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic Avoidance Task
Study: NCT00755638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031
Description: single subcutaneous dose of ACE-031
Study: NCT04995458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: composite-ceramic
Description: To assess the clinical performance of composite-ceramic crowns

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monolithic zirconia
Description: To assess the clinical performance of monolithic z¡irconia crowns
Study: NCT02350556

Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic Avoidance Task

Intervention type: PROCEDURE
Group type: OTHER
Intervention: physical therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: physical therapy

Intervention type: DEVICE
Group type: OTHER
Intervention: 3D motion on optoelectronic device

Intervention type: DEVICE
Group type: OTHER
Intervention: 3D motion on optoelectronic device
Study: NCT00676884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)
Description: 30 mgs s.c. b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1.5 mL s.c. b.i.d.
Study: NCT02698267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm
Study: NCT01655901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active video gaming

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active video gaming

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active video gaming
Study: NCT02698267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg twice daily \[BID\] on Day 8 and once daily (QD) from Day 9 to Day 15 inclusive
Study: NCT01655901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive video gaming

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive video gaming

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive video gaming
Study: NCT03747666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2.0 single locking miniplates
Description: The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates placed on the inferior border of the mandible.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2.0 single locking miniplates
Description: The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates placed on the inferior border of the mandible.
Study: NCT02854514

Intervention type: PROCEDURE
Intervention: Aspiration of endometrial secretion
Description: intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
Study: NCT01483391

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care
Description: The 3 family sessions involve the youth and all family members. These sessions will help the child and family members with mood charting and developing a mood management plan. Families will rehearse mood regulation strategies for current family, social or academic problems. Clinicians then meet with the child individually every month for the next 3 mos. to provide support, assist with problem-solving, and troubleshoot use of the mood management plan.
Study: NCT01655901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resting
Study: NCT01483391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment
Description: 12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. The goal of this intervention is to improve the child's ability to regulate moods and to reduce tension and conflict in the family.
Study: NCT00711984

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Herkulink renal artery Stent
Description: renal artery stent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: best medical therapy
Description: All patients will receive best medical therapy according to current guidelines consisting in antihypertensive, antiplatelet, antidiabetic and lipid-lowering medication and in recommendation of lifestyle modification

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: best medical therapy
Description: All patients will receive best medical therapy according to current guidelines consisting in antihypertensive, antiplatelet, antidiabetic and lipid-lowering medication and in recommendation of lifestyle modification
Study: NCT00330382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowman-Birk inhibitor concentrate
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01655901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resting
Study: NCT03861039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study: NCT02370108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical muscle stimulation
Description: electrical muscle stimulation at hand muscle for reduction tremor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical muscle stimulation
Description: electrical muscle stimulation at hand muscle for reduction tremor
Study: NCT01576809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin
Description: Single dose syrup containing a warming flavor IFF flavor 316 282, in a syrup containing Paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup
Study: NCT01303094

Intervention type: DRUG
Group type: OTHER
Intervention: Trabectedin
Description: Trabectedin will be administered without drug holiday in Arm A until unacceptable toxicity, progressive disease or patient decision. The treatment beyond disease progression and in case of intolerance will be decided according to investigator discretion. In case of progression after drug discontinuation by patient decision, a re-challenge of Trabectedin is possible.

Intervention type: OTHER
Group type: OTHER
Intervention: Drug: holiday
Description: A drug-holiday will start after the 6th cycle until disease progression, and then Trabectedin will be re-challenged. Trabectedin will be administered until unacceptable toxicity, second evidence of progressive disease or patient decision.
Study: NCT04334980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bacTRL-Spike
Description: Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1), 3 billion (Group 2) or 10 billion (Group 3) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
Study: NCT02810756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Pazopanib formulation
Study: NCT02641145

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: F-18 florbetapir/C-11 acetate PET
Description: F-18 florbetapir PET scan, C-11 acetate PET scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: F-18 florbetapir/C-11 acetate PET
Description: F-18 florbetapir PET scan, C-11 acetate PET scan
Study: NCT03861039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antihyperglycemic medication (OAM)
Description: Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antihyperglycemic medication (OAM)
Description: Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antihyperglycemic medication (OAM)
Description: Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
Study: NCT03385538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: increasing doses of clopidogrel depending on PRU values (75-300 mg)
Study: NCT02064244

Intervention type: OTHER
Intervention: Ultrasound for measurement of Inferior Vena Cava size.
Description: Focused bedside ultrasound will be performed for each patient as part of their routine care and initial assessment. The IVC size will be measured at the subcostal window, during inspiration and expiration, using the Sonosite cardiac probe P-21 (5-1 MHZ). The measurement is obtained by applying the M-mode, perpendicular to the IVC axis and 2 cm caudal from its junction with the right atrium.
Study: NCT02641145

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: F-18 florbetapir/C-11 acetate PET
Description: F-18 florbetapir PET scan, C-11 acetate PET scan

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: F-18 florbetapir/C-11 acetate PET
Description: F-18 florbetapir PET scan, C-11 acetate PET scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Cardiac MRI with gadolinium contrast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Cardiac MRI with gadolinium contrast.
Study: NCT02733419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: Participants will receive 90 mg enfuvirtide subcutaneously (SC) b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: Participants will receive 90 mg enfuvirtide subcutaneously (SC) b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: Participants will receive 90 mg enfuvirtide subcutaneously (SC) b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background antiretroviral regimen (OB)
Description: Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background antiretroviral regimen (OB)
Description: Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background antiretroviral regimen (OB)
Description: Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.
Study: NCT00548327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Comparison between Atomoxetine and Placebo
Study: NCT02641145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Cardiac MRI with gadolinium contrast.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Cardiac MRI with gadolinium contrast.
Study: NCT00548327

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional magnetic resonance imaging
Description: Comparison between Atomoxetine and Placebo arms

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Functional magnetic resonance imaging
Description: Comparison between Atomoxetine and Placebo arms
Study: NCT02641145

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: N-13 ammonia PET
Description: N-13 ammonia PET scan following supine bicycle stress.
Study: NCT02223377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
Study: NCT01314677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography (PET/CT)
Description: Undergo FDG PET/CT
Study: NCT00548327

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological Testing
Description: Comparison between Atomoxetine and Placebo arms

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Neuropsychological Testing
Description: Comparison between Atomoxetine and Placebo arms
Study: NCT01314677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography (PET/CT)
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography (PET/CT)
Description: Undergo FDG PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG PET/CT
Study: NCT02813551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torsemide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo